- Home
- AGIO vs FBNC Comparison
AGIO vs FBNC Comparison
Compare AGIO & FBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- FBNC
- Stock Information
- Founded
- AGIO 2007
- FBNC 1934
- Country
- AGIO United States
- FBNC United States
- Employees
- AGIO N/A
- FBNC N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- FBNC Major Banks
- Sector
- AGIO Health Care
- FBNC Finance
- Exchange
- AGIO Nasdaq
- FBNC Nasdaq
- Market Cap
- AGIO 2.4B
- FBNC 2.2B
- IPO Year
- AGIO 2013
- FBNC N/A
- Fundamental
- Price
- AGIO $41.13
- FBNC $48.83
- Analyst Decision
- AGIO Strong Buy
- FBNC Buy
- Analyst Count
- AGIO 4
- FBNC 4
- Target Price
- AGIO $59.33
- FBNC $56.67
- AVG Volume (30 Days)
- AGIO 514.0K
- FBNC 240.7K
- Earning Date
- AGIO 10-30-2025
- FBNC 10-22-2025
- Dividend Yield
- AGIO N/A
- FBNC 1.86%
- EPS Growth
- AGIO N/A
- FBNC N/A
- EPS
- AGIO 11.13
- FBNC 2.39
- Revenue
- AGIO $40,875,000.00
- FBNC $364,799,000.00
- Revenue This Year
- AGIO $23.74
- FBNC $36.35
- Revenue Next Year
- AGIO $159.90
- FBNC $8.41
- P/E Ratio
- AGIO $3.77
- FBNC $20.40
- Revenue Growth
- AGIO 30.57
- FBNC 0.59
- 52 Week Low
- AGIO $23.42
- FBNC $34.50
- 52 Week High
- AGIO $62.58
- FBNC $56.45
- Technical
- Relative Strength Index (RSI)
- AGIO 50.11
- FBNC 43.64
- Support Level
- AGIO $41.24
- FBNC $48.17
- Resistance Level
- AGIO $44.25
- FBNC $49.97
- Average True Range (ATR)
- AGIO 1.52
- FBNC 1.54
- MACD
- AGIO -0.16
- FBNC 0.11
- Stochastic Oscillator
- AGIO 31.28
- FBNC 53.15
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About FBNC First Bancorp
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing and investment advisory services.